166 related articles for article (PubMed ID: 35279028)
1. Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021.
Edelstein M; Wiegler Beiruti K; Ben-Amram H; Bar-Zeev N; Sussan C; Asulin H; Strauss D; Bathish Y; Zarka S; Abu Jabal K
Clin Infect Dis; 2022 Aug; 75(1):e572-e578. PubMed ID: 35279028
[TBL] [Abstract][Full Text] [Related]
2. Maternal and Cord Anti-SARS-CoV-2-Spike IgG following COVID-19 Vaccination versus Infection during Pregnancy: A Prospective Study, Israel October 2021-March 2022.
Abu Shqara R; Frank Wolf M; Mikhail Mustafa S; Sgayer I; Assulyn T; Abu Zraki A; Askhar Majadla N; Rechnizter H; Shehadeh M; Fleisher Sheffer V; Bordeynik-Cohen M; Yakir O; Lowenstein L; Sela E; Edelstein M; Dror AA
Am J Perinatol; 2024 May; 41(S 01):e1935-e1943. PubMed ID: 37164317
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-induced and hybrid immunity to SARS-CoV-2 after three or four doses of BNT162b2 - results from 22 months follow-up of a healthcare workers cohort, Israel, 2020-2022.
Edelstein M; Wiegler Beiruti K; Ben-Amram H; Beer N; Sussan C; Batya P; Zarka S; Abu Jabal K
Int J Infect Dis; 2023 Oct; 135():57-62. PubMed ID: 37572957
[TBL] [Abstract][Full Text] [Related]
4. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
5. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
6. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
[TBL] [Abstract][Full Text] [Related]
7. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel.
Shachor-Meyouhas Y; Hussein K; Dabaja-Younis H; Szwarcwort-Cohen M; Almog R; Weissman A; Mekel M; Hyams G; Horowitz NA; Gepstein V; Netzer I; Saban HC; Petersiel N; Tarabeia J; Halberthal M
Clin Microbiol Infect; 2022 Mar; 28(3):450.e1-450.e4. PubMed ID: 34838782
[TBL] [Abstract][Full Text] [Related]
9. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
10. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
11. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
12. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers.
Korodi M; Horváth I; Rákosi K; Jenei Z; Hudák G; Kákes M; Dallos-Fejér K; Simai E; Páll O; Staver N; Briciu V; Lupșe M; Flonta M; Almaș A; Birlutiu V; Daniela Lupu C; Magdalena Ghibu A; Pianoschi D; Terza LM; Fejer SN
Vaccine; 2022 Sep; 40(37):5445-5451. PubMed ID: 35931634
[TBL] [Abstract][Full Text] [Related]
14. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose.
Nevo L; Cahen-Peretz A; Vorontsov O; Frenkel R; Kabessa M; Cohen SM; Hamrani A; Oiknine-Djian E; Lipschuetz M; Goldman-Wohl D; Walfisch A; Kovo M; Neeman M; Yagel S; Wolf DG; Beharier O
Am J Obstet Gynecol; 2022 Sep; 227(3):486.e1-486.e10. PubMed ID: 35430228
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 immunogenicity in individuals infected before and after COVID-19 vaccination: Israel, January-March 2021.
Abu Jabal K; Ben-Amram H; Beiruti K; Brimat I; Abu Saada A; Bathish Y; Sussan C; Zarka S; Edelstein M
Epidemiol Infect; 2021 Aug; 149():e239. PubMed ID: 34399868
[TBL] [Abstract][Full Text] [Related]
16. Post-vaccination SARS-CoV-2 IgG spike antibody responses among clinical and non-clinical healthcare workers at a tertiary facility in Kenya.
Mwangi LW; Omuse G; Adam R; Ong'ete G; Matheka C; Mugaine P; Sayed S; Maina D
PLoS One; 2024; 19(4):e0299302. PubMed ID: 38573911
[TBL] [Abstract][Full Text] [Related]
17. The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.
Lumley SF; Wei J; O'Donnell D; Stoesser NE; Matthews PC; Howarth A; Hatch SB; Marsden BD; Cox S; James T; Peck LJ; Ritter TG; de Toledo Z; Cornall RJ; Jones EY; Stuart DI; Screaton G; Ebner D; Hoosdally S; Crook DW; Conlon CP; Pouwels KB; Walker AS; Peto TEA; Walker TM; Jeffery K; Eyre DW;
Clin Infect Dis; 2021 Aug; 73(3):e699-e709. PubMed ID: 33400782
[TBL] [Abstract][Full Text] [Related]
18. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
[TBL] [Abstract][Full Text] [Related]
19. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
[TBL] [Abstract][Full Text] [Related]
20. Post-vaccination antibody evaluation for nosocomial SARS-CoV-2 delta variant breakthrough infection.
Goto T; Tani N; Ikematsu H; Gondo K; Oishi R; Minami J; Onozawa K; Kuwano H; Akashi K; Shimono N; Chong Y
PLoS One; 2022; 17(7):e0272056. PubMed ID: 35877668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
